RecruitingNot ApplicableNCT07243639
Efficacy and Safety of Etrasimod in Elderly Patients With Ulcerative Colitis
A Prospective Study on the Efficacy and Safety of a Novel Oral Drug, Etrasimod, in Elderly Patients With Ulcerative Colitis
Sponsor
Showa Inan General Hospital
Enrollment
30 participants
Start Date
Oct 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Eligible patients will be identified in regular clinical practice. After providing thorough explanation and obtaining voluntary written informed consent, the clinical course, adverse events, endoscopic findings, and histopathological changes in biopsy specimens after Etrasimod administration will be prospectively collected and analyzed.
Eligibility
Inclusion Criteria1
- Patients with active ulcerative colitis
Exclusion Criteria1
- the presence of acute or chronic renal failure, chronic heart disease, pulmonary infection, liver cirrhosis, colorectal cancer, autoimmune disease, and infectious disease
Interventions
DRUGEtrasimod administration
2 mg of Etrasimod is orally administered everyday.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07243639